meningococcal disease
Recently Published Documents





2021 ◽  
Vol 29 (4) ◽  
pp. 259-264
Sigita Burokiene ◽  
Vitalija Mesceriakova ◽  
Agne Navickaite ◽  
Jonas Kairys ◽  
Vytautas Usonis

2021 ◽  
Vol 4 (6) ◽  
pp. 28805-28820
Luciete Almeida Silva ◽  
Lirna Salvioni Silva de Souza ◽  
Maria Jacirema Ferreira Gonçalves ◽  
David Eduardo Barroso

2021 ◽  
Vol 50 (1) ◽  
pp. 351-351
Rose Barry ◽  
Prithvi Raj Sendi Keshavamurthy ◽  
Paul Martinez ◽  
Balagangadhar Totapally

2021 ◽  
Vol Volume 14 ◽  
pp. 5261-5269
Chung Pham Van ◽  
The Trong Nguyen ◽  
Sy Tien Bui ◽  
Trong Van Nguyen ◽  
Huyen Thi Thanh Tran ◽  

2021 ◽  
Vol 21 (1) ◽  
Lorenzo Argante ◽  
Victoria Abbing-Karahagopian ◽  
Kumaran Vadivelu ◽  
Rino Rappuoli ◽  
Duccio Medini

Abstract Background The four-component serogroup B meningococcal 4CMenB vaccine (Bexsero, GSK) has been routinely given to all infants in the United Kingdom at 2, 4 and 12 months of age since September 2015. After 3 years, Public Health England (PHE) reported a 75% [95% confidence interval 64%; 81%] reduction in the incidence of serogroup B invasive meningococcal disease (IMD) in age groups eligible to be fully vaccinated. In contrast, vaccine effectiveness (VE) evaluated in the same immunization program applying the screening method was not statistically significant. We re-analyzed the data using an incidence model. Methods Aggregate data—stratified by age, year and doses received—were provided by PHE: serogroup B IMD case counts for the entire population of England (years 2011–2018) and 4CMenB vaccine uptake in infants. We combined uptake with national population estimates to obtain counts of vaccinated and unvaccinated person-time by age and time. We re-estimated VE comparing incidence rates in vaccinated and non-vaccinated subjects using a Bayesian Poisson model for case counts with person-time data as an offset. The model was adjusted for age, time and number of doses received. Results The incidence model showed that cases decreased until 2013–2014, followed by an increasing trend that continued in the non-vaccinated population during the immunization program. VE in fully vaccinated subjects (three doses) was 80.1% [95% Bayesian credible interval (BCI): 70.3%; 86.7%]. After a single dose, VE was 33.5% [12.4%; 49.7%]95%BCI and after two doses, 78.7% [71.5%; 84.5%]95%BCI. We estimated that vaccination averted 312 cases [252; 368]95%BCI between 2015 and 2018. VE was in line with the previously reported incidence reduction. Conclusions Our estimates of VE had higher precision than previous estimates based on the screening method, which were statistically not significant, and in line with the 75% incidence reduction previously reported by PHE. When disease incidence is low and vaccine uptake is high, the screening method applied to cases exclusively from the population eligible for vaccination may not be precise enough and may produce misleading point-estimates. Precise and accurate VE estimates are fundamental to inform public health decision making. VE assessment can be enhanced using models that leverage data on subjects not eligible for vaccination.

Sign in / Sign up

Export Citation Format

Share Document